First Patient Dosed in Phase 1 Trial of MCY-M11 in Ovarian Cancer, Peritoneal Mesothelioma

First Patient Dosed in Phase 1 Trial of MCY-M11 in Ovarian Cancer, Peritoneal Mesothelioma
MaxCyte has begun dosing participants in a Phase 1 trial to assess its lead CAR T-cell therapy, MCY-M11, for the treatment of advanced ovarian cancer and peritoneal mesothelioma patients who failed prior chemotherapy. Taking place at the National Cancer Institute at the National Institutes of Health and Washington University in St. Louis, the open-label study (NCT03608618) is expected to include 15

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *